BioNTech licenses bispecific antibody for cancer in $1 billion deal

The German mRNA giant BioNTech has sealed a pact worth up to $1 billion with Biotheus to develop the Chinese biotech company’s bispecific antibody cancer drug PM8002 in all territories except for Greater China.

Related Keywords

China ,Chinese ,Xiaolin Liu ,Pfizer ,Antibody Drug Conjugates ,Bio Developments ,Pipelines ,Bispecific Antibodies ,Monoclonal Antibodies ,Biotechnology ,Cell Culture ,Harmacology ,Iontech ,